The United States Food and Drug Administration has given the marketing clearance to Imaging Therapeutics’ OsDx™ Hip Bone Mineral Density (BMD) system. Designed to estimate the BMD of the proximal femur with the use of standard antero-posterior hip or pelvis radiographic images, the stand-alone X-ray image-processing software will assist physicians in assessing osteoporosis. The system will help in making BMD testing more accessible. Earlier detection will facilitate early drug intervention to treat fractures.